“…Though murine CD8 − and CD8 + DC subsets expressed IDO protein in response to IFNγ treatment, only CD8 + DCs produced kynurenine, indicating IDO enzyme activity (Fallarino et al, 2002). Systemic treatments with soluble CTLA4 (CTLA4-Ig) and relatively high doses of TLR9 ligands (CpGs) were also able to induce CD8 + DCs to express functional IDO by ligating B7 or TLR9 molecules and inducing IDO via IFNα signaling in a rare, but distinctive subset of splenic CD19 + DCs co-expressing CD8, the plasmacytoid DC (pDC) marker B220, as well as CD19 and other B cell markers (Grohmann et al, 2002; Mellor et al, 2003, 2005;Baban et al, 2005;Johnson et al, 2010). In humans, monocyte-derived DCs competent to express IDO in response to IFNγ were a discrete subset of DCs expressing the chemokine receptor CCR6 and the pDC marker CD123 (Munn et al, 2002), and human DCs expressing IDO in response to CpGs also exhibited pDC attributes (Chen et al, 2008).…”